P3 Health Partners Inc. (PIII) AI Stock Analysis

P3 Health Partners Inc., headquartered in Henderson, Nevada, is a patient-centered and physician-led company specializing in population health management across the United States. The company operates a network of clinics and wellness centers designed to enhance healthcare outcomes and patient satisfaction through integrated healthcare solutions. Focused on collaborative relationships between healthcare providers and patients, P3 Health Partners Inc. emphasizes preventive care and chronic disease management. Through physician leadership and advanced technologies, the organization delivers comprehensive, personalized care solutions intended to optimize community health outcomes.

P3 Health Partners Inc. delivered a five-year revenue compound annual growth rate of 58.6% from FY2019 to FY2025. Annual revenue expanded from $491.1M in FY2020 to $1.05B in FY2022, $1.27B in FY2023, and $1.50B in FY2024, before revenue fell 2.8% to $1.46B in FY2025. Operating margins were -5.8% in FY2020, -148.7% in FY2022, -13.3% in FY2023, -20.8% in FY2024, and -18.5% in FY2025. Net losses totaled -$31.4M in FY2020, -$270.1M in FY2022, -$57.8M in FY2023, -$135.8M in FY2024, and -$147.9M in FY2025. For the latest quarter ended June 30, 2026, revenue increased 8.6% year-over-year, supporting trailing twelve-month revenue of $1.50B and an operating margin of 10.7%.

As of June 30, 2026, P3 Health Partners Inc. held $21.3M in cash and short-term investments and $130.3M in total debt, resulting in net debt of $109.0M. Total assets stood at $654.4M and shareholders' equity was $72.2M, yielding a debt-to-equity ratio of 1.80 and a current ratio of 0.46. In FY2025, operating cash flow was -$91.2M and free cash flow was -$91.2M. Capital expenditures totaled $79,000 for FY2025, while the share count decreased 91.9% over five years.

With a closing price of $4.14 on October 16, 2026, P3 Health Partners Inc. has a market capitalization of $843.7M and an enterprise value of $302.0M. The stock trades at a price-to-sales multiple of 0.6x and an enterprise value-to-revenue multiple of 0.2x, below the 4.1x price-to-sales median of its US-listed Healthcare peers. Over the past year, PIII shares dropped 53.9%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock declined 99.2%, while the S&P 500 advanced 83.0%.

Covering analysts hold 1 Strong Buy, 0 Buy, 1 Hold, 0 Sell, and 0 Strong Sell ratings on the stock. The mean price target is $18.00, representing a 334.8% premium over the last close of $4.14. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.55B and an EPS of -$14.84. For the subsequent fiscal year, 1 analyst forecasts revenue of $1.70B and an EPS of -$13.88. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of P3 Health Partners Inc. (PIII). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PIII income statement, PIII balance sheet, PIII key metrics, PIII analyst forecast, PIII chart. See the PIII stock overview for the latest quote and news.